Tyra Biosciences reports Q3 EPS (50c), consensus (51c)

As of September 30, 2025, TYRA had cash, cash equivalents and marketable securities of $274.9M. TYRA’s current cash, cash equivalents and marketable securities are expected to allow TYRA to execute on its plans through at least 2027. “Our focus remains on patients – those living with skeletal dysplasia and bladder cancer who need improved, precise options of care,” said CEO Todd Harris. “Enrollment continues to progress across our BEACH301 and SURF302 Phase 2 studies, reflecting strong engagement from the clinical and patient communities. We are also expanding the Phase 2 development of dabogratinib into low-grade upper tract urothelial carcinoma, where FGFR3 alterations occur in approximately 85% of LG-UTUC cases, further reinforcing our commitment to addressing FGFR3-driven disorders. We believe 2026 will be a pivotal year for TYRA. We expect to report interim Phase 2 results that could validate dabogratinib’s broad potential across achondroplasia, IR-NMIBC and LG-UTUC.”